InvestorsHub Logo
Followers 58
Posts 10057
Boards Moderated 1
Alias Born 09/21/2016

Re: None

Thursday, 06/02/2022 8:01:47 PM

Thursday, June 02, 2022 8:01:47 PM

Post# of 458879
Lane Simonian-seeking alpha 6/02/22

[Despite a recent substantial drop in stock value (which has affected almost all drug companies working in the Alzheimer's space), Anavex has more than sufficient resources to complete its current trials: approximately $150 million in cash and cash equivalents (fiscal report). It is ahead of many of its competitors such as Cassava Sciences, Alector (ALEC), Athira (ATHA), and Annovis (ANVS) in terms of completion of a large-scale clinical trial for Alzheimer's disease. Based on its apparent mechanism of action and previous trial results, Anavex has the potential to set a benchmark which its competitors may not be able to reach./quote]

Looks good enough to make a mark...IMO.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News